Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.
Jason Westin, MD, MS, FACP
Advertisement
Articles by Jason Westin, MD, MS, FACP
Sitravatinib plus tislelizumab showed a confirmed investigator-assessed overall response rate of 30.4% in PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.
During a Targeted Oncology Case-Based Peer Perspectives virtual event, Jason Westin, MD, MS, evaluated the management of a 63-year-old patient with diffuse large B-cell lymphoma.
Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Advertisement
Latest Updated Articles
Current Treatment Options for DLBCL Besides R-CHOP ChemotherapyPublished: March 16th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
